Hypomanic/manic switch after transcranial magnetic stimulation in mood disorders: A systematic review and meta-analysis.
Active vs sham comparison
Adverse event
Hypomanic/manic switch
Mood disorders
Safety
Transcranial magnetic stimulation
Journal
World journal of psychiatry
ISSN: 2220-3206
Titre abrégé: World J Psychiatry
Pays: United States
ID NLM: 101610480
Informations de publication
Date de publication:
19 Aug 2021
19 Aug 2021
Historique:
received:
16
02
2021
revised:
24
03
2021
accepted:
20
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Nowadays there is an increasing use of transcranial magnetic stimulation (TMS) both in neurological and psychiatric fields. After Food and Drug Administration approval of TMS for the therapy of treatment-resistant depression, TMS has been widely used in the context of mood disorders (MD). However, growing reports regarding the possibility of developing hypomanic/manic switch (HMS) have generated concern regarding its use in MDs. To investigate the actual risk of developing HMS due to TMS in the treatment of MD. We led our research on PubMed, Scopus and Web of Science on March 22, 2020, in accordance to the PRISMA guidelines for systematic review. Only double blind/single blind studies, written in English and focused on the TMS treatment of MD, were included. A meta-analysis of repetitive TMS protocol studies including HMS was conducted using RevMan 5.4 software. The assessment of Risk of Bias was done using Cochrane risk of bias tool. This protocol was registered on PROSPERO with the CRD42020175811 code. Twenty-five studies were included in our meta-analysis: Twenty-one double blind randomized controlled trials (RCT) and four single blind-RCT (no. of subjects involved in active stimulation = 576; no. of subjects involved in sham protocol = 487). The most frequently treated pathology was major depressive episode/major depressive disorder, followed by resistant depression, bipolar depression and other MD. The majority of the studies used a repetitive TMS protocol, and the left dorsolateral prefrontal cortex was the main target area. Side effects were reported in eight studies and HMS (described as greater energy, insomnia, irritability, anxiety, suicidal attempt) in four studies. When comparing active TMS Applying the most usual protocols and the appropriate precautionary measures, TMS seems not to be related to HMS development.
Sections du résumé
BACKGROUND
BACKGROUND
Nowadays there is an increasing use of transcranial magnetic stimulation (TMS) both in neurological and psychiatric fields. After Food and Drug Administration approval of TMS for the therapy of treatment-resistant depression, TMS has been widely used in the context of mood disorders (MD). However, growing reports regarding the possibility of developing hypomanic/manic switch (HMS) have generated concern regarding its use in MDs.
AIM
OBJECTIVE
To investigate the actual risk of developing HMS due to TMS in the treatment of MD.
METHODS
METHODS
We led our research on PubMed, Scopus and Web of Science on March 22, 2020, in accordance to the PRISMA guidelines for systematic review. Only double blind/single blind studies, written in English and focused on the TMS treatment of MD, were included. A meta-analysis of repetitive TMS protocol studies including HMS was conducted using RevMan 5.4 software. The assessment of Risk of Bias was done using Cochrane risk of bias tool. This protocol was registered on PROSPERO with the CRD42020175811 code.
RESULTS
RESULTS
Twenty-five studies were included in our meta-analysis: Twenty-one double blind randomized controlled trials (RCT) and four single blind-RCT (no. of subjects involved in active stimulation = 576; no. of subjects involved in sham protocol = 487). The most frequently treated pathology was major depressive episode/major depressive disorder, followed by resistant depression, bipolar depression and other MD. The majority of the studies used a repetitive TMS protocol, and the left dorsolateral prefrontal cortex was the main target area. Side effects were reported in eight studies and HMS (described as greater energy, insomnia, irritability, anxiety, suicidal attempt) in four studies. When comparing active TMS
CONCLUSION
CONCLUSIONS
Applying the most usual protocols and the appropriate precautionary measures, TMS seems not to be related to HMS development.
Identifiants
pubmed: 34513609
doi: 10.5498/wjp.v11.i8.477
pmc: PMC8394688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
477-490Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no conflicts of interest.
Références
J Vis Exp. 2010 Nov 12;(45):
pubmed: 21189465
Exp Brain Res. 2001 Aug;139(4):465-72
pubmed: 11534871
Depress Anxiety. 2009;26(7):682-8
pubmed: 19170101
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Neuroimage Clin. 2018 May 23;19:661-674
pubmed: 30023172
Neurosci Biobehav Rev. 2019 Sep;104:118-140
pubmed: 31271802
Biol Psychiatry. 2007 Dec 1;62(11):1208-16
pubmed: 17573044
Eur Psychiatry. 2013 Jan;28(1):30-9
pubmed: 22559998
Neuromodulation. 2020 Apr;23(3):291-300
pubmed: 30896060
Am J Psychiatry. 2006 Jan;163(1):88-94
pubmed: 16390894
Int J Neuropsychopharmacol. 2008 Feb;11(1):119-30
pubmed: 17335643
BMC Psychiatry. 2019 Jan 8;19(1):13
pubmed: 30621636
Int J Neuropsychopharmacol. 2008 Feb;11(1):131-47
pubmed: 17880752
Mov Disord. 2005 Sep;20(9):1178-84
pubmed: 15895421
Brain Stimul. 2015 Mar-Apr;8(2):240-6
pubmed: 25541389
Ann Gen Psychiatry. 2013 Apr 24;12(1):12
pubmed: 23618105
Am J Psychiatry. 2014 Oct;171(10):1067-73
pubmed: 24935197
J Affect Disord. 2017 Sep;219:187-192
pubmed: 28558366
J Clin Psychopharmacol. 2007 Oct;27(5):488-92
pubmed: 17873682
Arch Gen Psychiatry. 2003 Oct;60(10):1002-8
pubmed: 14557145
Int J Cardiol. 2013 Mar 20;164(1):127
pubmed: 22795708
Brain Stimul. 2015 May-Jun;8(3):603-12
pubmed: 25697591
Neuropsychobiology. 2020;79(3):208-213
pubmed: 31955155
J Clin Psychopharmacol. 2008 Feb;28(1):52-8
pubmed: 18204341
Biol Psychiatry. 2001 Mar 1;49(5):468-70
pubmed: 11274660
Brain Behav. 2019 Oct;9(10):e01419
pubmed: 31566935
Australas Psychiatry. 2018 Apr;26(2):189-192
pubmed: 29338288
Lancet. 1996 Jul 27;348(9022):233-7
pubmed: 8684201
Annu Rev Biomed Eng. 2007;9:527-65
pubmed: 17444810
J Psychiatr Res. 2020 Jun;125:106-112
pubmed: 32251917
Psychiatry Res. 2004 Apr 30;126(2):123-33
pubmed: 15123391
J Clin Epidemiol. 2000 Sep;53(9):931-9
pubmed: 11004419
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:148-160
pubmed: 30641094
Eur Psychiatry. 2003 Jun;18(4):196-8
pubmed: 12814856
Brain Stimul. 2019 Jan - Feb;12(1):103-109
pubmed: 30237010
Clin Neurophysiol. 2017 Sep;128(9):1774-1809
pubmed: 28709880
Eur Psychiatry. 2004 Sep;19(6):382-3
pubmed: 15363481
Indian J Psychiatry. 2017 Jan;59(Suppl 1):S51-S66
pubmed: 28216785
Eur J Pharmacol. 2015 Jul 15;759:151-62
pubmed: 25814263
J Psychiatr Res. 2015 Jul-Aug;66-67:45-53
pubmed: 25937504
Shanghai Arch Psychiatry. 2015 Apr 25;27(2):103-10
pubmed: 26120260
Lancet. 2018 Apr 28;391(10131):1683-1692
pubmed: 29726344
Schizophr Res. 2018 Jul;197:34-44
pubmed: 29397282
Bipolar Disord. 2003 Feb;5(1):40-7
pubmed: 12656937
Neuropsychopharmacology. 2018 Oct;43(11):2231-2238
pubmed: 29946106
J Clin Neurophysiol. 2002 Aug;19(4):322-43
pubmed: 12436088
J Clin Psychiatry. 2018 Jan/Feb;79(1):
pubmed: 28541649
Epilepsy Behav. 2007 Jun;10(4):521-8
pubmed: 17493877
Brain Stimul. 2014 May-Jun;7(3):421-31
pubmed: 24731434
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Curr Psychiatry Rep. 2018 Feb 10;20(1):6
pubmed: 29427050
J Clin Psychiatry. 2004 Nov;65(11):1575-6
pubmed: 15554775
Neuroscience. 2010 May 5;167(2):323-8
pubmed: 20144692
Gen Psychiatr. 2019 Aug 12;32(4):e100074
pubmed: 31552384
Eur Addict Res. 2020;26(1):52-56
pubmed: 31665732
World Psychiatry. 2015 Feb;14(1):64-73
pubmed: 25655160
Biol Psychiatry. 2020 Mar 1;87(5):443-450
pubmed: 31563272
Brain Stimul. 2020 May - Jun;13(3):565-575
pubmed: 32289678
Neurophysiol Clin. 2019 Nov;49(5):371-375
pubmed: 31761447
Front Psychiatry. 2019 Sep 05;10:621
pubmed: 31543838
J Neurotrauma. 2019 Apr 15;36(8):1361-1374
pubmed: 30381997
J Neuropsychiatry Clin Neurosci. 2019 Fall;31(4):306-318
pubmed: 31018810
Nord J Psychiatry. 2004;58(6):455-7
pubmed: 16195088
Int J Geriatr Psychiatry. 2019 Jun;34(6):822-827
pubmed: 30854751
Indian J Psychol Med. 2011 Jan;33(1):35-44
pubmed: 22021951
Curr Psychiatry Rep. 2020 Mar 26;22(4):20
pubmed: 32215771
Behav Brain Res. 2009 Aug 12;201(2):239-43
pubmed: 19428640
Biol Psychiatry. 2005 Jan 15;57(2):162-6
pubmed: 15652875
Ann Phys Rehabil Med. 2015 Sep;58(4):208-213
pubmed: 26319963